<DOC>
	<DOCNO>NCT00452023</DOCNO>
	<brief_summary>The goal clinical research study see Pegasys ( IFN-alpha2a ) help control disease patient essential thrombocytosis ( ET ) , polycythemia vera ( PV ) , agnogenic myeloid metaplasia/myelofibrosis ( AMM/MF ) , Philadelphia chromosome-negative chronic myeloid leukemia ( Ph-negative CML ) . The safety treatment also study .</brief_summary>
	<brief_title>PegasysÂ® Patients With Myeloproliferative Diseases</brief_title>
	<detailed_description>IFN-alpha2a use treatment variety disorder ( hepatitis C ) . IFN-alpha2a drug may affect way infection malignant disease develop . Before treatment start , blood ( around 2 teaspoon ) bone marrow sample collect . To collect bone marrow sample , area hip chest bone numb anesthetic small amount bone marrow withdrawn large needle . These sample use test confirm diagnosis disease . Women able child must negative blood pregnancy test . During treatment , receive IFN-alpha2a injection skin week . You ( caregiver ) taught give injection , receive treatment outpatient basis . Treatment continue ( injection week ) long disease get bad . If disease get bad experience intolerable side effect , take study doctor discus treatment option . During treatment blood ( around 1 teaspoon ) collect every week 2 month , every 1 2 month year , every 3 month . You also bone marrow sample collect every 3 6 month first year treatment . After first year treatment , bone marrow sample collect doctor feel need . The blood bone marrow sample use test check response therapy . This investigational study . IFN-alpha2a approve FDA treatment hepatitis C commercially available . However use IFN-alpha2a study investigational . The commercial prepartion IFN-alpha2a ( Pegasys ) use study . Up 280 participant take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>1 . Following diagnosis : ET : Patients PLT &gt; 600 x10 9 /l document past 12 month ; hyperplasia marrow megakaryocytes absence identifiable cause thrombocytosis absence Ph chromosome . Patients ET low PLT eligible attributable prior ET therapy . PV : Patients Hb &gt; /= 15g/dl ( except patient phlebotomy do ) document past diagnosis . 2 . Performance status &lt; /= 2 ( ECOG scale ) . 3 . Age great 18 year since disease extremely rare young age group . 4 . Adequate liver function : total bilirubin &lt; /= 2.0 mg/dl ( except patient Gilbert 's Syndrome ) AST ( SGOT ) ALT ( SGPT ) &lt; 3 X ULN ( &lt; 5 X ULN consider due tumor ) , renal function ( serum creatinine &lt; /= 2.0 mg/dl ) . 5 . Signed informed consent indicate patient aware investigational nature study keep policy M.D . Anderson Cancer Center . The acceptable consent form one approve M.D . Anderson Cancer Center IRB . 6 . Willingness ability comply requirement protocol duration study . 7 . Patients must chemotherapy 1 week prior begin Pegasys recover toxic effect therapy . Patients may receive hydroxyurea anagrelide immediately study entry , may continue therapy treat physician determines best interest patient . 1 . Pregnant lactating woman . 2 . Patients prior history another malignancy concurrent malignancy , except follow : basal cell carcinoma skin , carcinoma situ cervix , malignancy patient disease free &gt; 3 year . 3 . Patients history ischemic retinopathy . 4 . Patients history severe cardiac disease : NYHA Functional Class III IV , myocardial infarction within 6 month , uncontrolled ventricular tachyarrhythmias unstable angina . 5 . Patients history medically significant psychiatric disease control , especially endogenous depression ( include reactive depression postcancer diagnosis ) , psychosis bipolar disease . 6 . Patients seizure disorder require anticonvulsant therapy . 7 . Patients know infection HBV , HIV , active systemic infection . 8 . Patients know autoimmune disease except rheumatoid arthritis . 9 . Patients renal disease hemodialysis . 10 . Patients take continuous chronic highdose systemic steroid ; discontinue , must minimum washout period one month study drug begin . 11 . Patients know hypersensitivity PEGIFN alpha2a component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Essential Thrombocythemia</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Pegasys</keyword>
	<keyword>IFN-alpha2a</keyword>
	<keyword>Pegylated-Interferon Alpha-2A</keyword>
	<keyword>PEG-IFNa-2a</keyword>
</DOC>